Thus, to identify druggable mechanisms underlying the early stages of Schwann cell tumor malignant transformation that may modify MEK inhibitor response prior to PRC2 mutation in patients with NF1-mutant, PRC2-intact neurofibromas, we performed genome-wide CRISPRi screens in NF1-mutant, PRC2-intact NF95.11b neurofibroma cells (Fig. 3a and Supplementary Data 8). The gene discussed is NF1; the disease is neurofibroma.